Topline data were announced from a phase 3 trial evaluating ceralasertib plus Imfinzi in patients with locally advanced or metastatic NSCLC.

Black and Hispanic/Latino patients with food allergies are less apt to recognize anaphylaxis and have more limited EAI access than White patients.

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Most people in the United States are happy with their health insurance, but many still struggle with denied claims, delays and rising costs.

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

Scrolling is still a big part of daily life for American teenagers, despite mounting worries about screen time and mental health.

Severe airflow obstruction was prevalent in children and adults with asthma, especially those who were extremely preterm or small for gestational age.

President Donald Trump signed an executive order that could make it easier for scientists to study cannabis for medical use.

COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.

Nearly 1 in 4 Americans believe the US health care system is in crisis, and high costs are the top reason why.

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

The HHS has ended several health grants to one of the nation’s largest pediatricians’ groups, a move the organization says could hurt children and families.